KR20040094793A - 안질환의 치료 또는 예방을 위한 각막 또는 실질내 투여용약제 - Google Patents

안질환의 치료 또는 예방을 위한 각막 또는 실질내 투여용약제 Download PDF

Info

Publication number
KR20040094793A
KR20040094793A KR10-2004-7014329A KR20047014329A KR20040094793A KR 20040094793 A KR20040094793 A KR 20040094793A KR 20047014329 A KR20047014329 A KR 20047014329A KR 20040094793 A KR20040094793 A KR 20040094793A
Authority
KR
South Korea
Prior art keywords
corneal
urea
cornea
eye
solution
Prior art date
Application number
KR10-2004-7014329A
Other languages
English (en)
Korean (ko)
Inventor
빅켄 카라게오지안
데이비드 카스틸레조스
존 파크
가브리엘 아투로 카피오 아라곤
조세 루이스 구티에르레스 플로레스
Original Assignee
비트레오-레티날 테크놀로지스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비트레오-레티날 테크놀로지스, 인크. filed Critical 비트레오-레티날 테크놀로지스, 인크.
Publication of KR20040094793A publication Critical patent/KR20040094793A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR10-2004-7014329A 2002-03-14 2003-03-14 안질환의 치료 또는 예방을 위한 각막 또는 실질내 투여용약제 KR20040094793A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36397902P 2002-03-14 2002-03-14
US60/363,979 2002-03-14
PCT/US2003/007700 WO2003077898A1 (en) 2002-03-14 2003-03-14 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye

Publications (1)

Publication Number Publication Date
KR20040094793A true KR20040094793A (ko) 2004-11-10

Family

ID=28041849

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7014329A KR20040094793A (ko) 2002-03-14 2003-03-14 안질환의 치료 또는 예방을 위한 각막 또는 실질내 투여용약제

Country Status (10)

Country Link
EP (1) EP1482922A4 (ru)
JP (1) JP2005522464A (ru)
KR (1) KR20040094793A (ru)
CN (1) CN1642536A (ru)
AU (2) AU2003213858A1 (ru)
BR (1) BR0308403A (ru)
CA (1) CA2478965A1 (ru)
MX (1) MXPA04008776A (ru)
RU (1) RU2363459C2 (ru)
WO (1) WO2003077898A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101231121B (zh) * 2007-01-24 2012-06-13 泰州乐金电子冷机有限公司 冰箱用托盘拉出装置

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
WO2011111876A1 (en) * 2010-03-12 2011-09-15 Riken Clearing reagent for biological material, and use thereof
CN107300496B (zh) 2011-05-20 2020-11-24 国立研究开发法人理化学研究所 生物材料用透明化试剂、及其利用
US10267714B2 (en) 2013-08-14 2019-04-23 Riken Composition for preparing biomaterial with excellent light-transmitting property, and use thereof
DE102013110608A1 (de) * 2013-09-26 2015-03-26 Florian Lang Substanz zur Hemmung von Gewebskalzifizierung, Gewebsfibrosierung und altersassoziierten Erkrankungen
CN110237238A (zh) * 2019-08-02 2019-09-17 山东省眼科研究所 Manf在促进角膜损伤修复中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
ATE396734T1 (de) * 1999-03-02 2008-06-15 Vitreo Retinal Technologies In Mittel für intravitreale verabreichung zur behandlung oder vorbeugung von augenerkrankungen
MXPA04007802A (es) * 2002-02-13 2005-04-19 Vitreo Retinal Technologies In Tratamiento de desordenes oftalmicos utilizando urea o derivados de urea.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101231121B (zh) * 2007-01-24 2012-06-13 泰州乐金电子冷机有限公司 冰箱用托盘拉出装置

Also Published As

Publication number Publication date
JP2005522464A (ja) 2005-07-28
AU2009201897B2 (en) 2011-09-15
CA2478965A1 (en) 2003-09-25
BR0308403A (pt) 2005-01-18
AU2003213858A1 (en) 2003-09-29
RU2363459C2 (ru) 2009-08-10
CN1642536A (zh) 2005-07-20
MXPA04008776A (es) 2005-04-19
RU2004129761A (ru) 2005-06-10
EP1482922A1 (en) 2004-12-08
EP1482922A4 (en) 2005-06-08
AU2009201897A1 (en) 2009-06-04
WO2003077898A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
Taneri et al. Evolution, techniques, clinical outcomes, and pathophysiology of LASEK: review of the literature
US7977385B2 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
CHEN et al. Trabeculectomy with simultaneous topical application of mitomycin-C in refractory glaucoma
Raiskup et al. Corneal crosslinking with riboflavin and ultraviolet A. Part II. Clinical indications and results
US5627162A (en) Methods and means for control of proliferation of remnant cells following surgery
Taneri et al. Surface ablation techniques
AU2009201897B2 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
Lam et al. Management of severe flap wrinkling or dislodgment after laser in situ keratomileusis
EP1165095B1 (en) Agents for intravitreal administration to treat or prevent disorders of the eye
Clinch et al. Treatment of contact lens-related ocular surface disorders with autologous conjunctival transplantation
Pfister Clinical measures to promote corneal epithelial healing
WO2019238107A1 (zh) 红景天苷及其衍生物在制备眼科纤维化细胞外基质蛋白异常疾病的抑制剂药物中的应用
Loon et al. A major review of antimetabolites in glaucoma therapy
Pushker et al. Neurotrophic keratopathy
MXPA01011025A (es) Metodos bioquimicos que eliminan las cicatrices, opacificacion y la bruma de la cornea.
Hondur et al. A prospective bilateral comparison of epi-LASIK and LASEK for myopia
US10016452B2 (en) Fibromodulin formulation for reducing corneal scarring
Yee et al. Update on laser subepithelial keratectomy (LASEK)
US20090099557A1 (en) Methods and compositions for optimizing the outcomes of refractive laser surgery of the cornea
WO2014142469A2 (ko) 안과 염증 질환 치료용 점안제 조성물 및 이의 제조 방법
EP1173207B1 (en) Miotic agents and hypertonic agents containing ophthalmic compositions
JPH08503968A (ja) 増殖因子と代謝拮抗物質を含有する組成物
KR100509421B1 (ko) 각막 상피하 혼탁 억제제
Gillies et al. Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy
WO2009088118A1 (en) Pharmaceutical composition for treating corneal wound comprising poly-gamma-glutamic acid

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application